Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Somite Therapeutics General Information
Somite Therapeutics is leveraging advanced AI models to develop protocols for producing human tissues from stem cells. Their lead programs are in preclinical development, targeting Duchenne muscular dystrophy and metabolic diseases. The company’s proprietary AlphaStem platform enables rapid discovery and optimization of cell differentiation protocols, aiming to accelerate the creation of new cell-based therapies[4][5][6].
Contact Information
Primary Industry
Biotech
Corporate Office
Boston, Massachusetts
USA
USA
Drug Pipeline
SMT-M01
Pre-clinicalKey Partnerships
OmniaBio Inc. (for GMP manufacturing and clinical translation)[5], Astellas Venture Management (investor/board observer)[3], Montage Ventures (investor/board observer)[3]
Somite Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Sep 3, 2024 | $4.8M | Completed | Preclinical |
To view Somite Therapeutics's complete valuation and funding history, request access »